SwePub
Sök i SwePub databas

  form:Ext_t

Träfflista för sökning "WFRF:(Yu Chong Jen) "

form:Search_simp_t: WFRF:(Yu Chong Jen)

  • navigation:Result_t 1-4 navigation:of_t 4
hitlist:Modify_result_t
   
hitlist:Enumeration_thitlist:Reference_thitlist:Reference_picture_thitlist:Find_Mark_t
1.
  •  
2.
  • Sampson, Joshua N., et al. (creator_code:aut_t)
  • Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for 13 Cancer Types
  • 2015
  • record:In_t: Journal of the National Cancer Institute. - : Oxford University Press (OUP). - 0027-8874 .- 1460-2105. ; 107:12
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • Background: Studies of related individuals have consistently demonstrated notable familial aggregation of cancer. We aim to estimate the heritability and genetic correlation attributable to the additive effects of common single-nucleotide polymorphisms (SNPs) for cancer at 13 anatomical sites. Methods: Between 2007 and 2014, the US National Cancer Institute has generated data from genome-wide association studies (GWAS) for 49 492 cancer case patients and 34 131 control patients. We apply novel mixed model methodology (GCTA) to this GWAS data to estimate the heritability of individual cancers, as well as the proportion of heritability attributable to cigarette smoking in smoking-related cancers, and the genetic correlation between pairs of cancers. Results: GWAS heritability was statistically significant at nearly all sites, with the estimates of array-based heritability, h(l)(2), on the liability threshold (LT) scale ranging from 0.05 to 0.38. Estimating the combined heritability of multiple smoking characteristics, we calculate that at least 24% (95% confidence interval [CI] = 14% to 37%) and 7% (95% CI = 4% to 11%) of the heritability for lung and bladder cancer, respectively, can be attributed to genetic determinants of smoking. Most pairs of cancers studied did not show evidence of strong genetic correlation. We found only four pairs of cancers with marginally statistically significant correlations, specifically kidney and testes (rho = 0.73, SE = 0.28), diffuse large B-cell lymphoma (DLBCL) and pediatric osteosarcoma (rho = 0.53, SE = 0.21), DLBCL and chronic lymphocytic leukemia (CLL) (rho = 0.51, SE = 0.18), and bladder and lung (rho = 0.35, SE = 0.14). Correlation analysis also indicates that the genetic architecture of lung cancer differs between a smoking population of European ancestry and a nonsmoking Asian population, allowing for the possibility that the genetic etiology for the same disease can vary by population and environmental exposures. Conclusion: Our results provide important insights into the genetic architecture of cancers and suggest new avenues for investigation.
  •  
3.
  • Wang, Zhaoming, et al. (creator_code:aut_t)
  • Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33
  • 2014
  • record:In_t: Human Molecular Genetics. - : Oxford University Press (OUP). - 0964-6906 .- 1460-2083. ; 23:24, s. 6616-6633
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • Genome-wide association studies (GWAS) have mapped risk alleles for at least 10 distinct cancers to a small region of 63 000 bp on chromosome 5p15.33. This region harbors the TERT and CLPTM1L genes; the former encodes the catalytic subunit of telomerase reverse transcriptase and the latter may play a role in apoptosis. To investigate further the genetic architecture of common susceptibility alleles in this region, we conducted an agnostic subset-based meta-analysis (association analysis based on subsets) across six distinct cancers in 34 248 cases and 45 036 controls. Based on sequential conditional analysis, we identified as many as six independent risk loci marked by common single-nucleotide polymorphisms: five in the TERT gene (Region 1: rs7726159, P = 2.10 × 10(-39); Region 3: rs2853677, P = 3.30 × 10(-36) and PConditional = 2.36 × 10(-8); Region 4: rs2736098, P = 3.87 × 10(-12) and PConditional = 5.19 × 10(-6), Region 5: rs13172201, P = 0.041 and PConditional = 2.04 × 10(-6); and Region 6: rs10069690, P = 7.49 × 10(-15) and PConditional = 5.35 × 10(-7)) and one in the neighboring CLPTM1L gene (Region 2: rs451360; P = 1.90 × 10(-18) and PConditional = 7.06 × 10(-16)). Between three and five cancers mapped to each independent locus with both risk-enhancing and protective effects. Allele-specific effects on DNA methylation were seen for a subset of risk loci, indicating that methylation and subsequent effects on gene expression may contribute to the biology of risk variants on 5p15.33. Our results provide strong support for extensive pleiotropy across this region of 5p15.33, to an extent not previously observed in other cancer susceptibility loci.
  •  
4.
  • Boutry, Céline, et al. (creator_code:aut_t)
  • The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster : Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
  • 2022
  • record:In_t: Clinical Infectious Diseases. - : Oxford University Press. - 1058-4838 .- 1537-6591. ; 74:8, s. 1459-1467
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • Efficacy against herpes zoster and immune responses to the adjuvanted recombinant zoster vaccine plateaued at high levels between 5.1 and 7.1 years (mean) post-vaccination, suggesting that its clinical benefit in older adults is sustained for at least 7 years post-vaccination. Background This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV) at age >= 50 years in 2 pivotal efficacy trials (ZOE-50 and ZOE-70). The present interim analysis was performed after >= 2 additional years of follow-up (between 5.1 and 7.1 years [mean] post-vaccination) and includes partial data for year (Y) 8 post-vaccination. Methods Annual assessments were performed for efficacy against herpes zoster (HZ) from Y6 post-vaccination and for anti-gE antibody concentrations and gE-specific CD4[2+] T-cell (expressing >= 2 of 4 assessed activation markers) frequencies from Y5 post-vaccination. Results Of 7413 participants enrolled for the long-term efficacy assessment, 7277 (mean age at vaccination, 67.2 years), 813, and 108 were included in the cohorts evaluating efficacy, humoral immune responses, and cell-mediated immune responses, respectively. Efficacy of RZV against HZ through this interim analysis was 84.0% (95% confidence interval [CI], 75.9-89.8) from the start of this follow-up study and 90.9% (95% CI, 88.2-93.2) from vaccination in ZOE-50/70. Annual vaccine efficacy estimates were >84% for each year since vaccination and remained stable through this interim analysis. Anti-gE antibody geometric mean concentrations and median frequencies of gE-specific CD4[2+] T cells reached a plateau at approximately 6-fold above pre-vaccination levels. Conclusions Efficacy against HZ and immune responses to RZV remained high, suggesting that the clinical benefit of RZV in older adults is sustained for at least 7 years post-vaccination.
  •  
Skapa referenser, mejla, bekava och länka
  • navigation:Result_t 1-4 navigation:of_t 4
swepub:Mat_t
swepub:mat_article_t (4)
swepub:Level_t
swepub:level_refereed_t (4)
swepub:Hitlist_author_t
Chang-Claude, Jenny (2)
Boutron-Ruault, Mari ... (2)
Boeing, Heiner (2)
Krogh, Vittorio (2)
Khaw, Kay-Tee (2)
Riboli, Elio (2)
deldatabas:search_more_t
Mannisto, Satu (2)
Weiderpass, Elisabet ... (2)
Haiman, Christopher ... (2)
Berndt, Sonja I (2)
Chanock, Stephen J (2)
Gapstur, Susan M (2)
Stevens, Victoria L (2)
Albanes, Demetrius (2)
Cancel-Tassin, Geral ... (2)
Travis, Ruth C (2)
Giles, Graham G (2)
Kogevinas, Manolis (2)
Gago Dominguez, Manu ... (2)
Johansen, Christoffe ... (2)
Feychting, Maria (2)
Sund, Malin (2)
Andersson, Ulrika (2)
Ahlbom, Anders (2)
Gallinger, Steven (2)
Visvanathan, Kala (2)
White, Emily (2)
Peters, Ulrike (2)
Severi, Gianluca (2)
Jenab, Mazda (2)
Vineis, Paolo (2)
Bueno-de-Mesquita, H ... (2)
Trichopoulos, Dimitr ... (2)
Canzian, Federico (2)
Tjonneland, Anne (2)
Boffetta, Paolo (2)
Peeters, Petra H. M. (2)
Hallmans, Göran (2)
Andrulis, Irene L. (2)
Hoover, Robert N. (2)
Kitahara, Cari M. (2)
Shu, Xiao-Ou (2)
Southey, Melissa C. (2)
Zheng, Wei (2)
Kraft, Peter (2)
Garcia-Closas, Monts ... (2)
Chatterjee, Nilanjan (2)
Diver, W Ryan (2)
Gaziano, J Michael (2)
Kolonel, Laurence N (2)
deldatabas:search_less_t
swepub:Hitlist_uni_t
swepub_uni:uu_t (3)
swepub_uni:umu_t (2)
swepub_uni:lu_t (1)
swepub_uni:bth_t (1)
swepub_uni:slu_t (1)
hitlist:Language_t
language:Eng_t (4)
hitlist:HSV_t
hsv:Cat_3_t (3)

hitlist:Year_t

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt tools:Close_t

tools:Permalink_label_t